SCHEMBL3103839

SCHEMBL3103839

O=C(NC1CCCCC1OCc1ccccc1)c1ccc([N+](=O)[O-])cc1

nearest known ligand 0.56

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
NPC1 O15118 4/20 0.56
RAB9A P51151 4/20 0.56
SMN1; SMN2 Q16637 2/20 0.51
TAAR1 Q96RJ0 1/20 0.51
PRKCB P05771 2/20 0.49
PRKCA P17252 2/20 0.49
PRKCE Q02156 2/20 0.49
PRKCG P05129 1/20 0.49
PRKCH P24723 1/20 0.49
PRKCD Q05655 1/20 0.49
BCHE P06276 1/20 0.48
GAA P10253 1/20 0.48
MAPT P10636 1/20 0.48
MEN1 O00255 2/20 0.47
KMT2A Q03164 2/20 0.47
MERTK Q12866 7/20 0.47
AXL P30530 5/20 0.47
MET P08581 1/20 0.47
TYRO3 Q06418 1/20 0.47
TP53 P04637 1/20 0.46

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL13156495 1.00 NPC1 (0.56) NPC1RAB9ASMN1; SMN2TAAR1PRKCB
SCHEMBL13156526 0.90 MERTK (0.51) PRKCBPRKCAPRKCEPRKCGPRKCH
SCHEMBL3096606 0.90 MERTK (0.51) PRKCBPRKCAPRKCEPRKCGPRKCH
SCHEMBL13181608 0.80 HDAC3 (0.48) NPC1RAB9ASMN1; SMN2MAPTMEN1
SCHEMBL13156519 0.80 NPC1 (0.52) NPC1RAB9AGAAMAPTMEN1
SCHEMBL3089032 0.80 NPC1 (0.52) NPC1RAB9AGAAMAPTMEN1
SCHEMBL30583807 0.79 NPC1 (0.62) NPC1RAB9AGAAMAPTMEN1
SCHEMBL7864067 0.79 CXCR1 (0.52) GAAMAPTMEN1KMT2A
SCHEMBL7864070 0.79 CXCR1 (0.52) GAAMAPTMEN1KMT2A
SCHEMBL27701237 0.78 KCNA5 (0.53) MAPTMEN1KMT2AMERTKAXL

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7799934-B2 Intermediates (synthons) in the synthesis of pharmaceuticals such as oseltamivir and other products; treating the arizidine with the nucleophile in the presence of a biaryl phosphoric acid catalyst UNIVERSITY OF SOUTH FLORIDA (US) 2010-09-21 US disclosed
US-20090030212-A1 Enantioselective ring-opening of aziridines UNIVERSITY OF SOUTH FLORIDA OF TAMPA 2009-01-29 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090030212-A1 Enantioselective ring-opening of aziridines AZI2, ITPA, ADORA2A NPC1 3406/4885RAB9A 557/4885SMN1; SMN2 3472/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.